Erratum to: Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study[Diabetologia(2015), DOI 10.1007/s00125-014-3473-8];Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study

Diabetologia

Volumn 58, Issue 3, 2015, Pages 505-518

  Kontopantelis, Evangelos ^a   Springate, David A ^a   Reeves, David ^a   Ashcroft, Darren M ^a   Rutter, Martin ^b,c   Buchan, Iain ^a   Doran, Tim ^d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Biological variables; Biometric; Blood pressure; Cholesterol; Complications; Diabetes; HbA1c; Macrovascular; Microvascular; Type 2

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL;

ADULT; ADVERSE OUTCOME; AGED; AMPUTATION; ARTICLE; BIOMETRY; BLOOD PRESSURE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DIABETIC FOOT; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; BLOOD; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84925537410     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3526-7     Document Type: Erratum

References (38)

1. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:4–14
2. Hex N, Bartlett C, Wright D, Taylor M, Varley D (2012) Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med J Br Diabet Assoc 29:855–862
3. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053
4. Turner RC, Millns H, Neil HA et al (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823–828
5. Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412
6. Adler AI, Stratton IM, Neil HA et al (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412–419
7. (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837–853
8. Miller ME, Williamson JD, Gerstein HC et al (2014) Effects of randomization to intensive glucose control on adverse events, cardiovascular disease and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care 37:634–643
9. Hemmingsen B, Lund SS, Gluud C et al (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343:d6898
10. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
11. Vamos EP, Harris M, Millett C et al (2012) Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ 345:e5567
12. Rutter MK (2012) Low HbA1c and mortality: causation and confounding. Diabetologia 55:2307–2311
13. Nilsson PM (2011) Target blood pressure in diabetes patients with hypertension–what is the accumulated evidence in 2011? J Zhejiang Univ Sci B 12:611–623
14. Rutter MK, Nesto RW (2011) Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. Eur Heart J 32:2247–2252
15. Cullen P, Schulte H, Assmann G (1997) The Munster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in nonsmokers. Circulation 96:2128–2136
16. Rywik SL, Manolio TA, Pajak A et al (1999) Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). Am J Cardiol 84:540–548
17. Kontopantelis E, Springate D, Reeves D, Ashcroft DM, Valderas JM, Doran T (2014) Withdrawing performance indicators: retrospective analysis of general practice performance under UK Quality and Outcomes Framework. BMJ 348:g330
18. Kontopantelis E, Reeves D, Valderas JM, Campbell S, Doran T (2013) Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study. BMJ Qual Saf 22:53–64
19. Springate DA, Kontopantelis E, Ashcroft DM et al (2014) ClinicalCodes: an online clinical codes repository to improve the validity and reproducibility of research using electronic medical records. PLoS One 9:e99825
20. Welch C, Bartlett J, Petersen I (2014) Application of multiple imputation using the two-fold fully conditional specification algorithm in longitudinal clinical data. Stata J 14:418–431
21. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B (2012) Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 380:37–43
22. Leong A, Dasgupta K, Bernatsky S, Lacaille D, Avina-Zubieta A, Rahme E (2013) Systematic review and meta-analysis of validation studies on a diabetes case definition from health administrative records. PLoS One 8:e75256
23. A'Court C, Stevens R, Sanders S, Ward A, McManus R, Heneghan C (2011) Type and accuracy of sphygmomanometers in primary care: a cross-sectional observational study. Br J Gen Pract J R Coll Gen Pract 61:e598–e603
24. Carey IM, Nightingale CM, DeWilde S, Harris T, Whincup PH, Cook DG (2009) Blood pressure recording bias during a period when the Quality and Outcomes Framework was introduced. J Hum Hypertens 23:764–770
25. Schafer JL, Graham JW (2002) Missing data: our view of the state of the art. Psychol Methods 7:147–177
26. Groenwold RHH, Donders ART, Roes KCB, Harrell FE, Moons KGM (2012) Dealing with missing outcome data in randomized trials and observational studies. Am J Epidemiol 175:210–217
27. Kontopantelis E, Buchan I, Reeves D, Checkland K, Doran T (2013) Relationship between quality of care and choice of clinical computing system: retrospective analysis of family practice performance under the UK's quality and outcomes framework. BMJ Open 3:e003190
28. Currie CJ, Peters JR, Tynan A et al (2010) Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 375:481–489
29. Andersson C, van Gaal L, Caterson ID et al (2012) Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia 55:2348–2355
30. Ahmed S, Cannon CP, Murphy SA, Braunwald E (2006) Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J 27:2323–2329
31. Shepherd J, Kastelein JJP, Bittner VA et al (2008) Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc 83:870–879
32. Group AS, Cushman WC, Evans GW et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585
33. Zhao WH, Katzmarzyk PT, Horswell R et al (2013) Aggressive blood pressure control increases coronary heart disease risk among diabetic patients. Diabetes Care 36:3287–3296
34. Silverman SL (2009) From randomized controlled trials to observational studies. Am J Med 122:114–120
35. Saunders C, Byrne CD, Guthrie B et al (2013) External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med 30:300–308
36. Association AD (2013) Standards of medical care in diabetes—2013. Diabetes Care 36:S11–S66
37. National Institute for Health and Care Excellence (2011) Diabetes in adults quality standard. In: NICE quality standard 6. NICE, London, pp 1–66
38. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596